


PRODUCT INFORMATION



Telratolimod

Item No. 33172

CAS Registry No.: 1359993-59-1
Formal Name: N-[4-[(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy]butyl]-octadecanamide
Synonyms: MEDI9197, 3M-052
MF: C₃₆H₅₉N₅O₂
FW: 593.9
Purity: ≥98%
UV/Vis.: λ_{max}: 248 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Telratolimod is supplied as a crystalline solid. A stock solution may be made by dissolving the telratolimod in the solvent of choice, which should be purged with an inert gas. Telratolimod is slightly soluble in ethanol and DMSO.

Description

Telratolimod is an agonist of toll-like receptor 7 (TLR7) and TLR8.¹ It increases the production of IL-8 in HEK293 cells expressing human TLR7 or TLR8 and increases protein levels of IFN-α and TNF-α in isolated human peripheral blood mononuclear cells (PBMCs). Telratolimod (1 mg/kg) increases the HA-induced secretion of IFN-γ in mouse splenocytes *ex vivo* but does not induce the production of TNF-α in mouse serum *in vivo*. Telratolimod nanoparticles, when used as an adjuvant with the HIV-1 envelope glycoprotein, enhance neutralizing antibody responses to an HIV-1 pseudovirus in rhesus macaques for at least one year.² Intratumoral administration of telratolimod reduces tumor growth and increases metastasis-free survival in E0771 and 4T1.2 murine mammary carcinoma models and increases intratumoral production of cytokines in a 4T1.2 murine model, an effect that is enhanced by coadministration of anti-PD-1 antibodies.³

References

1. Smirnov, D., Schmidt, J.J., Capecchi, J.T., *et al.* Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction. *Vaccine* **29**(33), 5434-5442 (2011).
2. Kasturi, S.P., Rasheed, M.A.U., Havenar-Doughton, C., *et al.* 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. *Sci. Immunol.* **5**(48), eabb1025 (2020).
3. Zanker, D.J., Spurling, A.J., Brockwell, N.K., *et al.* Intratumoral administration of the toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. *Clin. Transl. Immunology* **9**(9), e1177 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM